Martin H
Pharmaceutical Sciences
Biotec Pharmacon
Norway
Biography
Martin has over 30 years experience in the medtech industry in large multi-nationals, start-ups and public companies. He has served as a Board member in a variety of life science companies encompassing medical devices, diagnostics and biotech. Martin is a member of the NIHR Strategy Board. After 15 years in increasingly senior roles in large multi-nationals, Martin became CEO of biomaterials company Tissue Science Laboratories, which he took from start-up, through angel capital and a listing on London’s AiM market to trade sale to Covidien. Martin has considerable experience of the establishment and funding of early stage life science ventures and to date has raised over £50m to support the commercialisation of novel technologies. Mr Hunt holds no shares in Biotec Pharmacon.
Research Interest
Business
